Skip to main content
. 2022 May 6;14(5):999. doi: 10.3390/pharmaceutics14050999

Table 4.

Summary of predicted phenotypes observed in treatment-resistant patients.

Gene CYP1A2 CYP2C19 CYP2D6
Phenotype
Normal metaboliser 56% 34% 81%
Intermediate metaboliser - 32% 5%
Poor metaboliser - - 7%
Rapid or ultra-rapid metaboliser 44% 34% 7%
Gene SLC6A4
Phenotype
Normal expression or activity 20%
Intermediate expression or activity 51%
Reduced expression or activity 29%